JPWO2020161543A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020161543A5 JPWO2020161543A5 JP2021569596A JP2021569596A JPWO2020161543A5 JP WO2020161543 A5 JPWO2020161543 A5 JP WO2020161543A5 JP 2021569596 A JP2021569596 A JP 2021569596A JP 2021569596 A JP2021569596 A JP 2021569596A JP WO2020161543 A5 JPWO2020161543 A5 JP WO2020161543A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- hydroxyvitamin
- composition
- optionally
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 claims description 117
- 235000021318 Calcifediol Nutrition 0.000 claims description 117
- 238000000034 method Methods 0.000 claims description 98
- 210000002966 serum Anatomy 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 42
- 238000002560 therapeutic procedure Methods 0.000 claims description 24
- 230000037396 body weight Effects 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000013268 sustained release Methods 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 claims description 8
- 229930003316 Vitamin D Natural products 0.000 claims description 8
- 235000019166 vitamin D Nutrition 0.000 claims description 8
- 239000011710 vitamin D Substances 0.000 claims description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 8
- 229940046008 vitamin d Drugs 0.000 claims description 8
- 230000003442 weekly effect Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 4
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 claims description 3
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims description 3
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 238000002203 pretreatment Methods 0.000 claims description 3
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 claims description 2
- 102000013387 Vitamin D3 24-Hydroxylase Human genes 0.000 claims description 2
- 108010026102 Vitamin D3 24-Hydroxylase Proteins 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 238000001631 haemodialysis Methods 0.000 claims description 2
- 230000000322 hemodialysis Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710190440 Cytotoxin 1 Proteins 0.000 description 1
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 101710149067 Paired box protein Pax-5 Proteins 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960000413 doxercalciferol Drugs 0.000 description 1
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000987 paricalcitol Drugs 0.000 description 1
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024204631A JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802148P | 2019-02-06 | 2019-02-06 | |
| US62/802,148 | 2019-02-06 | ||
| PCT/IB2020/000089 WO2020161543A1 (en) | 2019-02-06 | 2020-02-06 | Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024204631A Division JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519789A JP2022519789A (ja) | 2022-03-24 |
| JPWO2020161543A5 true JPWO2020161543A5 (enExample) | 2023-02-14 |
Family
ID=69903711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569596A Pending JP2022519789A (ja) | 2019-02-06 | 2020-02-06 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
| JP2024204631A Pending JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024204631A Pending JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220226351A1 (enExample) |
| EP (1) | EP3920938A1 (enExample) |
| JP (2) | JP2022519789A (enExample) |
| KR (1) | KR20210126023A (enExample) |
| CN (1) | CN113573714A (enExample) |
| AU (2) | AU2020218639A1 (enExample) |
| CA (1) | CA3128153A1 (enExample) |
| MX (1) | MX2020011741A (enExample) |
| WO (1) | WO2020161543A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025094144A1 (en) | 2023-11-02 | 2025-05-08 | Eirgen Pharma Ltd. | Controlling loss of kidney function |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2640094C (en) | 2006-02-03 | 2015-04-14 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| PL2679228T3 (pl) | 2006-06-21 | 2018-07-31 | Opko Ireland Global Holdings, Ltd. | Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D |
| KR101495578B1 (ko) | 2007-04-25 | 2015-02-25 | 사이토크로마 인코포레이티드 | 비타민 ｄ 부족 및 결핍의 치료 방법 |
| SI2481400T1 (sl) * | 2007-04-25 | 2014-11-28 | Opko IP Holdings II, Inc. | Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec |
| FI3225243T3 (fi) | 2007-04-25 | 2025-10-13 | Opko Renal Llc | Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä |
| EP3112476B1 (en) | 2008-04-02 | 2023-08-02 | EirGen Pharma Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| AU2013203489B2 (en) * | 2008-07-24 | 2015-02-05 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration |
| EP3636280B1 (en) * | 2010-03-29 | 2025-05-14 | EirGen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| KR101847947B1 (ko) * | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| SG10201913863TA (en) * | 2016-03-28 | 2020-03-30 | Opko Ireland Global Holdings Limited | Methods of vitamin d treatment |
| JP7590184B2 (ja) * | 2018-04-03 | 2024-11-26 | オプコ アイルランド グローバル ホールディングス リミテッド | 肥満外科手術患者におけるカルシフェジオールの使用 |
-
2020
- 2020-02-06 EP EP20713085.7A patent/EP3920938A1/en active Pending
- 2020-02-06 KR KR1020217026559A patent/KR20210126023A/ko not_active Ceased
- 2020-02-06 MX MX2020011741A patent/MX2020011741A/es unknown
- 2020-02-06 JP JP2021569596A patent/JP2022519789A/ja active Pending
- 2020-02-06 US US17/429,278 patent/US20220226351A1/en active Pending
- 2020-02-06 CN CN202080020844.6A patent/CN113573714A/zh active Pending
- 2020-02-06 AU AU2020218639A patent/AU2020218639A1/en not_active Abandoned
- 2020-02-06 WO PCT/IB2020/000089 patent/WO2020161543A1/en not_active Ceased
- 2020-02-06 CA CA3128153A patent/CA3128153A1/en active Pending
-
2024
- 2024-11-25 JP JP2024204631A patent/JP2025031720A/ja active Pending
-
2025
- 2025-10-30 AU AU2025259887A patent/AU2025259887A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abani et al. | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial | |
| JP3529790B2 (ja) | 続発性上皮小体機能亢進症の治療のための薬剤の製造におけるビタミンｄ▲下２▼又はビタミンｄ▲下４▼誘導体の用途 | |
| FI3225243T3 (fi) | Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä | |
| KR101495578B1 (ko) | 비타민 ｄ 부족 및 결핍의 치료 방법 | |
| JP2017075183A5 (enExample) | ||
| US5622941A (en) | Oral 1 α-hydroxyprevitamin D | |
| JP2004531468A5 (enExample) | ||
| CZ20012178A3 (cs) | Léčivo pro prevenci a léčení zdravotních stavů vyvolaných konstrikcí buněk hladkého svalstva | |
| JP2010525079A5 (enExample) | ||
| CA2048395A1 (en) | Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin | |
| Patel et al. | Ezetimibe (Zetia): a new type of lipid-lowering agent | |
| HK1052655A1 (zh) | 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑 | |
| JP2025031720A5 (enExample) | ||
| NL2013645C2 (en) | Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients which have been subjected to gastric bypass-surgery. | |
| JPWO2020161543A5 (enExample) | ||
| CA2563058A1 (en) | Supportive treatment of liver disease | |
| EP3658159A1 (en) | Pharmaceutical composition for use in the treatment or prevention of vitamin deficiency and mineral deficiency in patients who have been subjected to gastric sleeve surgery | |
| Yassa et al. | Incidence of tardive dyskinesia in an outpatient population | |
| Christakos | Vitamin D and breast cancer | |
| Kötter et al. | Human recombinant interferon-α2a (rhIFNα2a) for the treatment of Behçet’s disease with sight-threatening retinal vasculitis | |
| IL308206A (en) | Nasal sleep formulation | |
| Breijo-Márquez | Misuse of the Drug Acenocoumarol in a Population of 250 Inhabitants with Non-valvular Atrial Fibrillation Assessed in a Region of Southeaster of Spain | |
| MXPA02008998A (es) | Tratamiento de trastornos relacionados con el sistema serotonergico. | |
| Kumar et al. | Use of Intravenous Immunoglobulin in Severe Covid 19 Infection-A Potential Game Changer | |
| Wenstrup et al. | Is the combination of pharmacotherapy and nonpharmacotherapy more effective than nonpharmacotherapy alone at improving sleep-onset insomnia? |